Niagen Bioscience Inc (NAGE) — Titan Protect Analysis

NAGE

Niagen Bioscience Inc

Healthcare · ·

$3.45

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$277M

Total market value of the company

Trailing P/E

16.55

Reasonably valued

Forward P/E

10.86

Based on estimated future earnings — lower means cheaper

Rev Growth

+3.3%

Year-over-year revenue change

Profit Margin

14.3%

How much profit the company keeps from each dollar of revenue

ROE

27.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+248% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Niagen Bioscience Inc

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, in

https://www.niagenbioscience.com

Country: United States Employees: 117 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.483

Positive but modest risk-adjusted returns

Kelly Fraction

0.0211

Modest edge detected — smaller position warranted

Calmar Ratio

0.140

Drawdown risk outweighs the returns — higher risk profile

Annual Return

10.7%

Historical annualised return based on price data

Max Drawdown

-76.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.17

Significantly more volatile than the market

52W High

$14.69

77% below the year high

52W Low

$3.47

-0% above the year low

Avg Volume

1,215,636

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.21

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.13

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

64.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

5.0%

Profit from core operations before interest and tax

Free Cash Flow

$-1,861,500

Negative — the business is spending more than it generates

Revenue (TTM)

$130M

Total revenue over the last 12 months

Net Income

$19M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$12.00

Target Low

$10.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Sale	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go